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Purpose: Transplant recipients in Asia appear to be at a higher risk for developing 
colorectal cancer (CRC). This study was performed to identify the clinicopatho-
logical features and oncologic outcomes of CRC in post-renal transplants in Ko-
rea. Materials and Methods: We retrospectively reviewed the records of 17 pa-
tients with CRC out of 2,630 recipients who underwent renal transplantation 
between 1994 and 2007. These patients (transplant group) were compared with 
general CRC patients (n=170, control group) matched, based on the closest date of 
surgery to the transplant group. Results: During 29.7 months of the median fol-
low-up period, the recurrent and survival rates from recurrence were worse in the 
transplant group than in the control group (35.2% versus 15.2%; p=0.048 and 
p=0.025). The 2-year patient survival rate of the transplant group was significantly 
worse than the control group in advanced cancer (stages III-IV; 45.7% versus 
71.6%; p=0.023). In early cancer (stages 0-I), there was no significant difference in 
5-year patient survival rate between the two groups (100% versus 92.6%, respec-
tively; p=0.406). Conclusion: In spite of a poor prognosis of advanced CRC in the 
transplant group, the early stage CRC of the transplant group showed a compara-
ble oncologic outcome compared with the control group. Regular screening and 
early detection of CRC are essential in the post-transplant setting.
Key Words:    Colorectal cancer, post-transplant malignancy, oncologic outcome
INTRODUCTION
Improvements in immunosuppressive agents led to significantly enhanced graft 
survival.1 As a result, transplant recipients have greater accumulations and longer 
exposure to immunosuppressive agents than ever before. Unfortunately, however, 
long-term exposure to immunosuppressive agents can cause severe side effects, in-
cluding a variety of malignancies that have become major obstacles for long-term 
survival in transplant recipients.2 Many reports regarding de novo malignancies af-
ter transplantation have presented the incidence of post-transplant malignancies 
only.3-6 A few reports about oncologic outcomes of solid organ cancer after trans-Colorectal Cancer in Renal Transplant 
Yonsei Med J   http://www.eymj.org   Volume 52   Number 3   May 2011 455
care System. This database was collected prospectively for 
a previous CRC study.14,15 Based on the closest date of sur-
gery, we matched 10 patients to each kidney transplantation 
patient who subsequently developed de novo CRC.
Preoperative diagnosis and staging
Diagnostic evaluations included physical examination, colo-
noscopy, or abdominopelvic CT with double contrast, chest 
X-ray, complete blood cell count, liver function test, and 
measurements of serum carcinoembryonic antigen (CEA) 
levels. Standardized pathology analysis was performed on 
all radical rectal resection specimens. Rectal tumors were 
staged according to the 6th UICC TNM staging system. Re-
section specimens were evaluated for depth of tumor pene-
tration, lymph node involvement, histologic type, and lym-
phovascular invasion.  
Postoperative combined modality therapy
Stage III, IV patients and high risk stage II patients who 
had combined poorly differentiated tumor or lymphovascu-
lar invasion or neural invasion received a 5-flurouracil-leu-
covorin (FL) regimen consisting of 425 mg/m2 of 5-fluoro-
uracil plus 30 mg leucovorin for 5 days every 28 days for 12 
cycles, according to tumor stage. Some of the patients who 
had undergone renal transplantation were treated with oral 
5-fluorouracil-based chemotherapy; the remainder of those 
with advanced stage disease did not receive chemotherapy 
because of incompatibility with immunosuppressants.
　
Follow-up assessment
All patients were followed up every 3 months for the first 3 
years after surgery, every 6 months for the next 2 years, and 
yearly thereafter. Follow-up examinations included clinical 
history, physical examination, serum CEA levels, chest X-
ray, abdominopelvic CT or magnetic resolution imaging 
(MRI). Positron emission tomography (PET) scanning was 
used if available. Determination of recurrence was made by 
clinical and radiologic examinations, or by histologic con-
firmation. 
　
Statistical analysis 
Statistical evaluation was carried out using the SPSS statis-
tical package for Windows (version 11.0; SPSS Inc., Chica-
go, IL, USA). Differences between the two groups were 
tested with Student’s t-test, Fisher’s exact test, and a Chi-
squared test. The local and systemic recurrence rates were 
calculated with a Chi-squared test. The overall survival and 
plantation showed more aggressive and poorer oncologic 
outcomes than the general population.7,8 However, the clini-
cal research involving colorectal cancer (CRC) is very lim-
ited, although the incidence of CRC after renal transplanta-
tion is 1.5-2 times higher than the standard incidence.9-11 
Accordingly, we evaluated CRC in a large group of post-re-
nal transplant recipients at a single center in Korea over a 
25-year period in which the incidence of post-transplant 
CRC is higher in the Asian population than in the Western 
population.12,13 We compared the distinctiveness and onco-
logic outcomes of patients who had de novo CRC after re-
nal transplantation with the outcomes of the general CRC 
population at the same center.
MATERIALS AND METHODS
Patient selection  
Between September 1994 and November 2007, 2,630 pa-
tients underwent renal transplantation at Severance Hospi-
tal of the Yonsei University Healthcare System. Malignan-
cies developed in 190 patients, including 17 (8.9%) cases 
of CRC. None of the transplantation patients had solid or-
gan cancer, as confirmed by a computed tomography (CT) 
scan prior to transplantation. We performed colonoscopy 
for patients over 50 years old, based on Korean cancer 
guideline, but routinely performed for all patients prior to 
transplantation. After transplantation, patients routinely un-
derwent physical examination and had renal function tested 
in an outpatient clinic. If patients suffered gastrointestinal 
discomfort, esophagogastroscopy and colonoscopy were 
performed like general population group, although not rou-
tinely. We used maintenance immunosuppressive therapy 
with an azathioprine-based regimen from 1979-1984. Cy-
closporine became the main immunosuppressive agent in 
1984, followed by tacrolimus in 1998. We did not use in-
duction immunosuppression therapy, such as anti-thymo-
cyte globulin, anti-lymphocyte globulin, or muromonab-
CD3, but started induction therapy with interleukin-2 
receptor antibody (Basiliximab) for high-risk recipients in 
1999. 
Control group patient selection from the general CRC 
population
We selected control patients from the colorectal database, 
which contained about 6,000 cases recorded from 1994-
2007 at Severance Hospital of the Yonsei University Health-Jeong Yeon Kim, et al.
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the three cases of adenocarcinoma confined to the submu-
cosa were treated by endoscopic mucosal resection. Three 
patients had a family history of gastrointestinal cancer; of 
the three patients, two had a family history of colorectal 
cancer and one had a family history of gastric cancer.   
Comparison of characteristics between CRC in the 
transplant and control groups
A summary of patient characteristics from the transplant 
CRC and control CRC group is presented in Table 2. There 
were no significant differences in age and gender between 
the two groups (p=0.253 and p=0.426, respectively). The 
combined rate of distant metastasis and the rate of curative 
resection also did not differ significantly between the two 
groups (p=0.292 and p=0.440, respectively). The rate of as-
cending colon cancer was significant higher, and the rate of 
rectal cancer was significantly lower in the transplant group 
than in the control group (35.2% versus 15.4% and 33.5% 
versus 46.5%, respectively, p=0.031). In the transplant group, 
the incidence of combined polypectomy during pre-operative 
colonoscopy was higher (p=0.025) and the polyp size was 
greater (p=0.02) than in the control group. The average initial 
CEA level was higher in the transplant group, but the differ-
ence was not significant (p=0.917). There was no statistical 
significance in combining the metachronous cases of CRC 
between the two groups (p=0.382), but double primary tu-
mors were more common in the transplant group (p=0.030). 
　
Clinicopathologic characteristics
A summary of the clinicopathologic characteristics of the 
patients is presented in Table 3. We found no significant dif-
ferences in staging, histologic type, or lymphovascular in-
vasion between the two groups (p=0.320, p=0.324, and 
p=0.341, respectively). In the transplant group, the total num-
ber of harvested lymph nodes was significantly less than in 
control patients (6.6±3.20 versus 23.08±17.49, respective-
ly; p<0.0001), but the number of positive lymph nodes did 
not differ significantly between the two groups (2.2±2.28 
versus 1.90±0.58, respectively; p=0.324). 
Adjuvant treatment 
In the transplant group, patients with stage III and IV tu-
mors were not adequately treated with adjuvant chemora-
diotherapy compared to control patients (stage III: 66.7% 
versus 86.6%, stage IV: 50% versus 76%, respectively, 
p=0.012). Among chemotherapy patients, all 2 stage III 
transplant patients (100%) were treated with oral FL che-
disease-free survival rate were calculated with the Kaplan-
Meier method. Differences between curves were evaluated 
with the log-rank test. A value of p<0.05 was considered 
statistically significant.   
RESULTS
  
Characteristics of patients with de novo CRC after 
transplantation 
The characteristics of patients who developed de novo CRC 
subsequent to transplantation are summarized in Table 1. 
The mean follow-up duration was 195.3±11.5 months 
(range, 0-338 months). Malignancy occurred in 190 (7.2%) 
of 2,630 renal transplant recipients. Of the 190 patients, 17 
(8.9%) developed CRC. The average age of the patients 
with CRC was 54±7 years, and the average time to develop 
cancer after kidney transplantation was 129.7±65.4 months. 
Twelve of 17 patients (70.58%) were treated with cyclospo-
rine and steroids as an immunosuppressant regimen, 3 pa-
tients (17.6%) were treated with azathiopurine, cyclospo-
rine, and steroids, and 2 patients (11.7%) were treated with 
azathiopurine and steroids. Two patients suffered rejection 
prior to the development of cancer. Of the 17 CRC patients, 
Table 1. Characteristics of Post-Renal Transplant Patients 
with de novo Colorectal Malignancy 
Clinical manifestations
Colorectal malignancy  n=17
    Age at transplant  41±9
    Age at malignancy diagnosis 54±7
    Male : Female 11 : 6
    Time to develop malignancy 
      (months after transplantation)
129.7±65.4
    Donor type
        Living donor : Deceased donor 11 : 6
    Immunosuppressive (%)
        CsA+PRD 12 (70.58%)
        CsA+PRD+AZA 3 (17.6%)
        AZA+PRD  2 (11.7%)
    Rejection before malignancy development
        Yes : No 2 : 15
    Treatment method
        Operation  14 
        Endoscopic mucosal resection     3
    Gastrointestinal family history
        Colorectal : stomach 2 : 1
        None 14
CsA, cyclosporine; PRD, prednisolone; AZA, azathioprine.Colorectal Cancer in Renal Transplant 
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(Table 4). In systemic recurrence, carcinomatosis was sig-
nificantly higher in the transplant group than in control 
group (p=0.037) 
There were significant differences in the 5-year survival 
between the two groups (control, 67.8% versus transplant, 
40.2%; p=0.044)(Fig. 1). However, the 5-year survival rate 
for those with early cancer (stages 0-I) was not significantly 
different between the two groups (100% versus 92.6%, re-
spectively, p=0.406)(Fig. 2A). Although, there were signifi-
cant differences in the 2-year survival rate between the 
transplant and control groups for patients with advanced 
cancer (stages III-IV; 45.7% versus 71.6%, respectively; 
p=0.023)(Fig. 2B). 
In subanalysis, stage III-IV CRC patients in the trans-
plant group who were treated with adjuvant chemotherapy 
were compared with the advanced CRC in controls who 
motherapy, whereas all 52 stage III control patients were 
treated with intravenous chemotherapy (100%). One of two 
stage IV transplant patients (50%) was treated with intrave-
nous chemotherapy, whereas all 19 stage IV control patients 
were treated with intravenous chemotherapy (100%)(Table 
4). Of 5 chemotherapy patients, 2 patients lost the graft 
within 1 year of adjuvant chemotherapy.
Oncologic outcomes
The median follow-up period was 29.69 months (range, 
1-118 months). The incidence of local, systemic, and com-
bined recurrence among transplant group patients was 0%, 
35%, and 0%, and 1.7%, 11.1%, and 2.3% among control 
group patients, respectively. The overall rate of recurrence 
was significantly higher in the transplant group patients than 
in the control group patients (35.2% versus 15.2%, p=0.048) 
Table 2. Patient Characteristics in Colorectal Cancer with Adenocarcinoma
Transplant group (n=17)   Control group (n=170) p value
Age 54±7 58±10 0.253
Gender 0.426
        Female 6 (35.2%) 61 (35.9%)
        Male 11 (64.8%)  109 (64.1%)
Location 0.031
        Ascending 6 (35.2%) 26 (15.4%)
        Transverse 2 (11.7%) 2 (7.0%)
        Descending 1 (5.9%) 6 (3.5%)
        Sigmoid 2 (11.7%) 47 (27.6%)
        Rectum 6 (33.5%) 79 (46.5%)
Distant metastasis 0.292
        Yes 4 (23%) 24 (14.2%)
        No 13 (77%) 146 (85.8%)
Double primary tumor 0.030
        Yes 4 (23%) 13 (7.7%)
        No 13 (77%) 157 (92.3%)
Metachronous CRC 0.382
        Yes 1 (5.9%) 4 (2.3%)
        No 16 (94.1%) 166 (97.7%)
Preoperative-colonoscopic polypectomy 0.025
        Yes 9 (53%) 46 (27.1%)
        No 8 (47%) 124 (72.9%)
Polyp size* 1.72±0.84 1.01±0.49 0.020
Polyp histology
† 0.696
        Adenomaouts polyp 5 (55.6%) 22 (47.8%)
        Hyperplastic polyp 3 (33.3%)  13 (28.3%)
        Not determined 1 (11.1%) 11 (23.9%)
CEA, pre-operative  61.31±47.89 19.61±10.8 0.917
Treatment mode 0.440
        Curative  15 (88.2%) 156 (91.7%)
        Palliative 2 (11.8%) 14 (8.3%)
CRC, colorectal cancer; CEA, carcinoembryonic antigen.
*Only polyp size.
†Polyp histology were compared in combined polypectomy patients.Jeong Yeon Kim, et al.
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were treated with adjuvant chemotherapy. 2-year survival 
rates were 69.5% in control group and 53.3% in transplant 
group. In the transplant group, all patients died within 2.5 
years (p=0.031)(Fig. 3). 
There was no significant difference in mean time to recur-
rence from surgery between groups (p=0.837)(Table 5), 
however, the survival rate from recurrence was significantly 
lower in the transplant group than control patients (p=0.025) 
(Fig. 4). 
DISCUSSION
Recent evidence indicates that transplantation patients ap-
Table 3. Clinicopathological Characteristics
Transplant group  (n=17) Control group (n=170) p value
TNM staging 0.320 
    Stage 0   2 (11.7%) 12 (7.0%)  
    Stage I   5 (29.4%)   18 (10.5%)
    Stage II   3 (17.6%)     55 (32.35%)
    Stage III   3 (17.6%)     60 (35.29%)
    Stage IV   4 (23.5%)   25 (14.7%)
LN harvest  <0.001
    No. dissected node  6.6±3.20 23.08±17.49
    No. positive node 2.2±2.28 1.90±0.58
Histology 0.324
    Well differentiated   5 (29.4%)     30 (17.64%)
    Moderate differentiated 11 (64.7%)   120 (70.58%)
    Poorly differentiated 0 (0%) 11 (6.4%)
    Mucinous or signet 1 (5.8)   9 (5.2%)
Lymphovascular invasion 0.341
    Yes    6 (35.2%)    42 (24.7%)
    No 11 (64.7%)   128 (75.29%)
LN, lymph node.
Table 4. Adjuvant Chemotherapy 
Transplant group (n=10) Control group (n=140) p value
Chemotherapy* 
    Yes : No (%) 5 (50%) : 5 (50%) 120 (85.7%) : 20 (14.2%)   0.012
        Stage II 1 (33.3%) : 2 (66.7%) 49 (89.0%) : 6 (10.9%)
        Stage III 2 (66.7%) : 1 (33.3%) 52 (86.6%) : 8 (13.3%)
        Stage IV 2 (50%) : 2 (50%) 19 (76%) : 6 (24%)
Chemotherapy mode (%)
†
    Oral : Intravenous  4 (66.7%) : 1 (33.3%)          3 (2.5%) : 117 (97.5%) <0.001
        Stage II 1 (100%) : 0 (0%)       3 (6%) : 46 (54%)
        Stage III 2 (100%) : 0 (0%)         0 (0%) : 52 (100%)
        Stage IV 1 (50%) : 1 (50%)         0 (0%) : 19 (100%)
*Stage II, III, IV patients were selected and compared between transplant group (n=10) and control group (n=140). 
†Patients were compared between two group who were treated with adjuvant chemotherapy.
Fig. 1. Overall patient survival rate. Transplant group showed inferior sur-
vival rate compared with control group (p=0.044). 
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and an additional 2.2-fold higher after the third post-trans-
plantation year than with the general population (Table 6). 
However, less effort has been made to identify specific 
characteristics or oncologic outcomes in CRC in post-renal 
transplant recipients. In our study, we could not perform 
separate analysis of colon and rectum, because of not 
pear to be at a higher risk for developing CRC.9 Villeneuve, 
et al.11 described an incidence of CRC after renal transplan-
tation, showing 1.49 times higher than the standard inci-
dence. Furthermore, Kasiske, et al.10 reported the risk of co-
lon cancer development in post-renal transplantation patients 
to be two-fold higher in the first post-transplantation year, 
Table 5. Recurrence Pattern According to Type of Cancer 
Recurrence pattern Transplant group (n=17) Control group (n=170) p value
Local recurrence 0 3 (1.7%)
Systemic recurrence 6 (35.2%) 19 (11.1%) 0.037
    Liver metastasis 2 7
    Lung metastasis 0 6
    Carcinomoatosis 4 3
    Other organ 0 3
Local and systemic recurrence 0 4 (2.3%)
Total  6 (35.2%) 26 (15.2%) 0.048
Time to recurrence (month) 25.13±9.16 26.84±19.5 0.837
Fig. 2. Survival rate by pathologic staging. Early staged transplant group showed survival rate comparable to control group (p=0.406)(A), but advanced 
staged transplant group showed extremely poor survival rate compared with control group (p=0.023)(B). 
Fig. 3. The advanced staged colorectal cancer (CRC) in transplant group 
which were treated with adjuvant chemotherapy also showed poor surviv-
al rate compared with advanced stage CRC in control group who were 
treated with adjuvant chemotherapy (p=0.031).
Fig. 4. Survival rate after tumor recurrence. Transplant group had poor sur-
vival rate after tumor recurrence compared with control group (p=0.025).  
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lar, transplant recipients with advanced stage malignancies 
showed relatively poor oncologic outcome compared to 
controls. In our study, the 2-year survival rate of post-renal 
transplant patients with stage III-IV CRC was 45.7% com-
pared to 71.6% in general CRC patients. The 5-year surviv-
al of stage III-IV patients in the transplant group was 0%. 
Furthermore, we compared the survival rate of stage III-IV 
CRC patients who were treated with adjuvant chemothera-
py between the transplant and control groups. Although the 
2-year survivals in the transplant group were not inferior to 
the control group (69.5% versus 53.3%), transplant recipi-
ents showed poor oncologic outcomes compared to controls. 
All recipients died within 2.5 years of surgery (p=0.031). 
CRC seems to progress faster after diagnosed in an ad-
vanced stage following transplantation compared to the 
general population. We observed more frequent recurrence 
in transplant patients, compared to the general population 
group of CRC (35.2% versus 15.2%), and the recurrence 
pattern in post-renal transplant recipients was entirely sys-
temic recurrence, especially carcinomatosis (p=0.037). Fur-
thermore, when the tumor recurred, the survival period was 
less than 12 months after recurrence. The overall survival 
of stage IV patients in transplant was less than 10 months, 
and stage III patients in transplant were died within 25 
months. Such faster progression in advanced stage suggest 
a role for immunosuppression included increased host sus-
ceptibility to tumorigenesis and cancer progression.18
It is highly likely that the decreased survival for ad-
vanced cancer were not only due to immunosuppressive 
drugs, but also through ineffective treatment of CRC by ad-
juvant chemotherapy. Although our sub-analysis (Fig. 3) 
provided an evidence for decreased survival in the adjuvant 
cases, however, the fact that only 4 transplant patients with 
CRC were included compared to 71 controls should be tak-
en into account. Due to small numbers, it would be a possi-
ble limitation to conclude that advanced stage showed 
poorer survival compared to general population, regardless 
of adjuvant chemotherapy. We found that recipients with 
enough cases of rectal cancer, especially advanced stage 
rectal cancer in transplant recipients. 
 We observed that CRC in post-renal transplantation pa-
tients displayed atypical characteristics in both tumor loca-
tion, polyp size and occurrence. Our study showed that the 
rate of right CRC in the transplantation group was signifi-
cantly higher than in the general cancer population group 
(35.2% versus 15.4%, respectively), while the rate of rectal 
cancer was significantly lower in the transplantation group 
(33.5% versus 46.5%; p=0.031). Similar to our data, Stew-
art, et al.16 postulated that transplantation reduces the inci-
dence of rectal cancer. The results indicate that lympho-
glandular complexes are most frequent in the rectum. Thus, 
in the rectum compared to the colon, there is an increased 
capacity for antigen transport into a dense population of 
lymph follicles with a higher percentage of germinal cen-
ters. Abolition of such weak immune promotion of onco-
genesis by chronic immunosuppression would explain the 
highly significant reduction in the incidence of rectal can-
cer.16 However, we cannot be sure whether the transplant 
increased the incidence of right colon cancer and decreased 
the incidence of rectal cancer. Our data showed a tendency 
of more frequent right colon cancer and less frequent rectal 
cancer, compared to the general population. More observa-
tion or data are needed to conclude the higher incidence of 
right colon cancer and the lower incidence of rectal cancer. 
In terms of polyps, more and larger polyps were observed 
in preoperative colonoscopy of transplant patients. Al-
though the result of Parikshak, et al.17 shows that the inci-
dence of adenomatous polyps was not higher in post-renal 
transplant recipients compared with the general population, 
more combined polypectomies were performed at preoper-
ative colonoscopy in our transplantation group (p=0.025). 
Furthermore, the polyps observed in our post-renal trans-
plant recipients were significantly larger than in control pa-
tients (p=0.02). 
Oncologic outcomes were poorer in transplant recipients 
than in the general CRC population (p=0.044). In particu-
Table 6. Incidence of Colorectal Cancer in Post-Transplant Recipients
Reference
Transplantation 
period
No. of patients 
transplantation
Total No. 
of cancer (%)
No. of 
colorectal cancer
Kasiske, et al.
10 1995-2003 35,765   NA (14.9%) NA (0.51%)
Adami, et al.
3 1970-1997   5,931   629 (10.6%) 48 (0.8%)
HKTR
4  1962-1976 19,631   290 (1.47%)   9 (3.1%)
Penn
5   1962-1976 15,000 425 (2.8%) 11 (2.5%)
Ro, et al.
13 1969-2006   1,006   47 (4.3%)     5 (10.6%)
NA, not applicable; HKTR, human kidney transplant registry.Colorectal Cancer in Renal Transplant 
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after 55 years of age. Additionally, the mean exposure to 
the immunosuppressive agent is a significant risk factor in 
transplant recipients. Although a recent study showed that 
CRC in the transplant recipient developed at an earlier age 
compared to the general population,9,11 our data showed that 
age at diagnosis of the transplant recipient was not different 
from that of the control group. We do not regard younger 
age as an important risk factor, but long-term exposure to 
immunosuppression. Our present data showed the mean de-
velopment time of malignancy was 129.7±65.4 months fol-
lowing transplantation, and our previous study showed that 
the relative ratio of CRC development compared to age-
standardized incidence of malignancy in the Korean gener-
al population was 0.7 within 6-9 years, 2.1 within 9-12 
years, 4.9 within 12-15 years, 8.9 within 15-18 years.24 
Based on our study, a screening colonoscopy is recom-
mended within 6-9 years after transplantation. Additionally, 
earlier screening should be considered, when there is an an-
other risk factor, such as a family history of gastrointestinal 
cancer. Although not statistically significant, colon cancer 
developed at 45 years of age, 6 years after transplant, in a 
patient who had a family history of colon cancer.  
Our study has another limitation; we did not analyze the 
risk based on the type of immunosuppressant. Actually, our 
data showed no transplant patients who developed CRC 
treated with tacrolimus, although tacrolimus was used from 
1998. We enrolled patients for follow up more than 5 years 
after cancer surgery, however, there are very limited num-
bers of patients who used tacrolimus before 2004, and the 
use of tacrolimus took only 6 years since 2004. Therefore, 
it is highly likely that the duration exposed to tacrolimus is 
not enough to develop CRC in our study. 
Conclusion, de novo CRC in renal transplant patients has 
a poor oncologic outcome, high recurrence rate, and poor 
survival rate when the cancer is advanced. Cancer detected 
at early stages, however, can be overcome. Regular and rou-
tine screening for CRC prevention and early detection are 
essential for post-transplantation recipients. Guidelines are 
needed for screening and prevention of CRC in renal trans-
plant recipients. 
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